期刊文献+

表皮生长因子受体基因突变临床检测方法学比较及其影响因素分析 被引量:6

Methodology comparison and influence factors analysis of epidermal growth factor receptor mutation detection
原文传递
导出
摘要 目的 比较临床常用的两种方法检测晚期非小细胞肺癌(NSCLC)表皮生长因子受体(EGFR)基因突变状态结果的差异,探讨福尔马林固定石蜡包埋(FFPE)组织切片标本的不同保存方式对DNA数量、质量及对检测结果的影响.方法 收集中国医学科学院肿瘤医院2010年11月至2011年8月晚期NSCLC FFPE组织切片标本150份,分别采用楔形探针扩增阻滞突变系统(ScorpionsARMS)和直接测序法检测EGFR第18、19、20、21号外显子突变状态,分析两种方法检测EGFR基因突变结果的差异,对结果不一致病例收集临床治疗情况及生存数据并进行分析.对其中30份FFPE标本提取DNA并保存于-20℃3年,同样的30份FFPE标本按常规方法保存3年后再提取DNA,比较两种保存方式对DNA的数量、质量及对检测结果的影响.结果 Scorpions ARMS法检测EGFR基因突变的成功率(100%)高于直接测序法(87.3%),差异有统计学意义(χ^2=20.28,P<0.05).两种方法检测EGFR基因突变的一致率为84.7%,一致性较好(Kappa=0.738,P<0.001).分析结果不一致病例中5例接受靶向药物治疗后患者的生存情况,与ARMS检测结果一致性相对较好.新鲜FFPE标本提取并贮存于-20℃、3年的DNA与FFPE标本按常规方法保存3年后提取的DNA相比,后者质量相对较差,片段化程度更严重,但两种保存方法获取的DNA的EGFR基因突变检测结果均一致.结论 Scorpions ARMS与直接测序法联合检测结果更为全面、可靠.检测结果不确定的患者应以临床治疗及生存资料支持诊断.FFPE标本提取DNA后低温贮存,更有利于DNA完整性的保存. Objective To compare two different methods in detecting epidermal growth factor receptor(EGFR) mutation status of non-small cell lung cancer (NSCLC),and investing the influences of different conserving methods in DNA quantity,quality and detecting results of formalin-fixed paraffin embedded (FFPE) tissue samples.Methods One hundred and fifty FFPE samples of advanced NSCLC were collected in Cancer Institute/Hospital,Chinese Academy of Medical Sciences from November 2010 to August 2011.Both scorpions amplification refractory mutation system(scorpions ARMS)and direct sequencing were used to detect EGFR mutation in exon 18,19,20 and 21,together analyzed the differences between these two methods.Samples with inconsistent results were collected clinical treatment and survival information for further analysis.Extracted DNA from 30 FFPE samples and conserved at-20 ℃ for 3 years,meanwhile the same 30 FFPE samples DNA were extracted after conserving for 3 years.The DNA quantity、quality and testing results of the two conserving methods were compared.Results The detection success rate of Scorpions ARMS (100%) was higher than direct sequencing (87.3%),with statistical significance (χ^2 =20.28,P 〈 0.05).The consistent rate of the two methods was 84.7%,and there were no significant differences between these two methods,with a high consistence (Kappa =0.738,P 〈 0.001).The clinical treatment and survival status of 5 patients with different testing results were analysed,which were consistent with ARMS testing results.The quality of DNA extracted from FFPE tissues which were conserved for 3 years according to the conventional way was worse and with more fragments compared with DNA conserved at -20 ℃ for 3 years,but the EGFR mutation detecting results of the DNA acquired from the two conserved ways were consistent.Conclusions Combination of Scorpions ARMS and direct sequencing could make the detecting result more comprehensive and reliable.Clinical treatment and survival data may provide di
出处 《中华医学杂志》 CAS CSCD 北大核心 2015年第2期106-111,共6页 National Medical Journal of China
基金 国家高技术研究发展计划(2011AA02A110) 国家重大新药创制科技重大专项(2012ZX09303012) 国家自然科学基金(81372384) 北京市自然科学基金(7141010) 北京市科委重大项目(D141100000214003)
关键词 肺肿瘤 表皮生长因子受体 基因突变 直接测序 楔形探针扩增阻滞突变系统 Lung neoplasms Epidermal growth factor receptor Gene mutation Direct sequencing Scorpions amplification refractory mutation system
  • 相关文献

参考文献24

  • 1Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations- functional impact and relevance for lung cancer therapy [ J ]. Oncogene,2007,26 ( 39 ) : 5693-5701. 被引量:1
  • 2Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy [ J]. Cancer Lett, 2007,254 ( 2 ) : 165-177. 被引量:1
  • 3Yatabe Y. EGFR mutations and the terminal respiratory unit[ J]. Cancer Metastasis Rev,2010,29 ( 1 ) :23-36. 被引量:1
  • 4Shi Y, Au J S K,Thongprasert S, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Nan-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) [ J ]. J Thorac Oncnl, 2014,9 ( 2 ) : 154- 162. 被引量:1
  • 5Keedy V L,Temin S, Somerfield M R, et al. American Society of Chnical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy [J]. J Clin Oncol, 2011,29 (15) :2121-2127. 被引量:1
  • 6Giaccone G, Rajan A, Berman A, et al. Phase I1 study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors[ J]. J Clin Onco1,2011,29 ( 15 ) :2052-2059. 被引量:1
  • 7赫捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:12-25. 被引量:197
  • 8Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[ J ].Science, 2004,304(5676) :1497-1500. 被引量:1
  • 9Janne PA,Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-sinai1 cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[ J]. Clin Cancer Res,2006,12 ( 14 Suppl) :4416s-4420s. 被引量:1
  • 10Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[ J]. Lancet Oncol,2013,14(10) :953-961. 被引量:1

二级参考文献40

共引文献217

同被引文献42

  • 1田子强,刘俊峰,王贵英,Eric Smith,Paul Drew,David Watson,Glyn G Jamieson.甲醛固定石蜡包埋组织中DNA的降解情况[J].中华病理学杂志,2004,33(3):292-293. 被引量:4
  • 2向华,王坚,孙孟红,陆磊,水若鸿,朱雄增.黏液样/圆细胞型脂肪肉瘤石蜡包埋组织中FUS-CHOP融合基因检测的临床病理学意义[J].中华病理学杂志,2005,34(1):28-32. 被引量:8
  • 3何方刚,刘亚玲,舒细记,任亮,朱方成,王琦玮,王树发,黄知军,刘良.不同温度下离体人脾细胞DNA降解的差异性研究[J].中国法医学杂志,2005,20(6):321-324. 被引量:9
  • 4Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015, 65(1): 5-29. 被引量:1
  • 5Shi Y, Zhang L, Liu X, et al. lcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (1COGEN): a ran- domised, double-blind phase 3 non-inferiority trial [J]. Lancet Oneol, 2013, 14(10): 953-961. 被引量:1
  • 6Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and fi-nal overall survival results from a phase Ill, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol, 2011,29(21): 2866-2874. 被引量:1
  • 7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-pacli- taxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361 (10): 947-957. 被引量:1
  • 8Shi Y, Joseph Sk, Thongprasert S, et al. A Prospective, Molecular Epi- demiology Study of Adenocarcinoma Histology (PIONEER) [J]. Jour- nal of Thoracic Oncology, 2014, 9(2): 154-162. 被引量:1
  • 9Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity(mutmapll) [J]. Am J Cancer Res, 2015, 5(9): 2892-2911. 被引量:1
  • 10Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology ol lung cancer: key to personalized medicine [J]. Mod Pathol, 2012, 25 (3): 347-369. 被引量:1

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部